observed an independent prognostic feature of OX40 when they assessed the effect of PD-L1 co-expression, suggesting that OX40 is a stronger driver of survival than PD-L1 in non-small-cell lung cancer (30). Here, TNFRSF4 is linked to non-small cell lung carcinoma.